Rexahn Pharmaceuticals, Inc. (REXN)


Stock Price Forecast

Nov. 5, 2020


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Rexahn Pharmaceuticals, Inc. chart...

About the Company

Rexahn Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of oncology therapeutics. Its drug candidates include the following: RX-31171 for pancreatic, bladder, colon, and lung cancer; and RX-5902 for metastatic triple negative breast cancer. The company was founded by Chang Ho Ahn on March 19, 2001 and is headquartered in Rockville, MD.

Sector

Health Technology

Industry

Biotechnology

Employees

5

CEO

Douglas J. Swirsky

Exchange

NASDAQ

Website

http://www.rexahn.com

$1M

Total Revenue

5

Employees

$7M

Market Capitalization

-1.16

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $REXN News

Buy Rating Affirmed for Ocuphire Pharma on Promising APX3330 Progress for Diabetic Retinopathy Treatment

7d ago, source:

H.C. Wainwright analyst Matthew Caufield reiterated a Buy rating on Ocuphire Pharma (OCUP – Research Report) today and set a price target ...

Lexicon stock rallies 18% amid FDA update, $250M private placement

on MSN ago, source:

Lexicon (LXRX) stock rallied 18% amid a regulatory update for its diabetes drug candidate sotagliflozin and the announcement ...

Amring Pharmaceuticals Rebrands as Nordic Pharma, Eyes Global Expansion with Strategic Acquisition

6d ago, source: MyChesCo on MSN

BERWYN, PA — Amring Pharmaceuticals Inc. has announced a corporate name change to Nordic Pharma, Inc., marking a new chapter ...

Marinus Pharmaceuticals: Q4 Earnings Snapshot

13d ago, source:

(MRNS) on Tuesday reported a loss of $41.8 million in its fourth quarter. The Radnor, Pennsylvania-based company said it had a loss of 74 cents per share. The results did not meet Wall Street ...

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Q4 2023 Earnings Call Transcript

11d ago, source: InvestingChannel on MSN

Q4 2023 Earnings Call Transcript March 5, 2024 Marinus Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...